Source-grounded facts extracted from HAEMONETICS CORP's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
HAEMONETICS CORP reported financial results for the fourth quarter and fiscal year ended March 28, 2026.
“On May 7, 2026, Haemonetics Corporation issued a press release announcing financial results for the fourth quarter and fiscal year ended March 28, 2026.”
Charles J. Dockendorff departed as Director at HAEMONETICS CORP.
“On April 27, 2026, Charles J. Dockendorff informed Haemonetics Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Shareholders (the “2026 Annual Meeting”).”
Frank W. Chan was appointed as Executive Vice President, Chief Operating Officer at HAEMONETICS CORP.
“On March 3, 2025, Haemonetics Corporation (the “Company”) announced the appointment of Frank W. Chan, Ph.D. as its Executive Vice President, Chief Operating Officer, effective April 7, 2025.”
Josep Llorens retired as Executive Vice President, Global Manufacturing and Supply Chain at HAEMONETICS CORP.
“Josep Llorens, Executive Vice President, Global Manufacturing and Supply Chain, has notified Haemonetics Corporation (the “Company”) of his decision to retire from the Company effective July 11, 2025.”
Anila Lingamneni departed as Executive Vice President, Chief Technology Officer at HAEMONETICS CORP.
“Anila Lingamneni, Executive Vice President, Chief Technology Officer, will leave Haemonetics Corporation (the “Company”) on November 1, 2024.”
HAEMONETICS CORP reported financial results for the fourth quarter and fiscal year ended March 30, 2024.
“Item 2.02 Results of Operations and Financial Condition. On May 9, 2024 , Haemonetics Corporation issued a press release announcing financial results for the fourth quarter and fiscal year ended March 30, 2024.”
HAEMONETICS CORP incurred revolving credit of $750 million senior unsecured revolving credit facility with JPMorgan Chase Bank, N.A., as administrative agent at Adjusted Term SOFR Rate plus an applicable rate ranging from 1.125% to 1.750% maturing April 30, 2029.
“The Revised Credit Agreement provides for a $250 million senior unsecured term loan, the proceeds of which have been used to retire the balance of the term loan under the 2022 Credit Agreement, and a $750 million senior unsecured revolving credit facility, which constitutes a $330 million increase from the revolving credit facility under the 2022 Credit Agreement.”
HAEMONETICS CORP incurred credit facility of $250 million senior unsecured term loan with JPMorgan Chase Bank, N.A., as administrative agent at Adjusted Term SOFR Rate plus an applicable rate ranging from 1.125% to 1.750% maturing April 30, 2029.
“The Revised Credit Agreement provides for a $250 million senior unsecured term loan, the proceeds of which have been used to retire the balance of the term loan under the 2022 Credit Agreement, and a $750 million senior unsecured revolving credit facility, which constitutes a $330 million increase from the revolving credit facility under the 2022 Credit Agreement.”
HAEMONETICS CORP amended Revised Credit Agreement with JPMorgan Chase Bank, N.A. valued at $250 million senior unsecured term loan (effective 2024-04-30).
“On April 30, 2024, Haemonetics Corporation (the “Company”) entered into a second amended and restated credit agreement by and among the Company, as borrower, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “Revised Credit Agreement”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.